Trevogrumab

Trevogrumab (REGN1033) is a fully human monoclonal antibody that directly binds and neutralizes myostatin (GDF-8), preventing it from activating its receptor and inhibiting muscle growth. Unlike bimagrumab which blocks the ActRII receptor, trevogrumab targets the ligand itself, providing more selective myostatin inhibition.

This selectivity may offer advantages by specifically blocking myostatin while preserving signaling by other ActRII ligands like activins and GDF11 that have roles beyond muscle. However, it also means potentially less comprehensive muscle growth stimulation compared to receptor-blocking approaches.

Trevogrumab gained significant attention when Regeneron and Eli Lilly announced a clinical trial combining it with semaglutide, specifically aimed at preserving lean muscle mass during GLP-1 agonist-induced weight loss. This represents a novel approach to addressing the muscle loss that typically accompanies significant weight reduction.

The combination strategy reflects growing recognition that optimal metabolic therapy may require multiple agents targeting different pathways - GLP-1 for appetite and glucose control, with myostatin inhibition to protect muscle mass. Success of this approach could establish a new paradigm for comprehensive metabolic disease treatment.